Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

psoriatic arthritis
psoriatic arthritis
Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.

The following article is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .

CHICAGO — Statin therapy may lower C-reactive protein (CRP) levels in patients with psoriatic arthritis (PsA), according to a study presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois.

Researchers in this retrospective study examined data from the University of Tennessee Knoxville Patient Database on 206 patients with PsA for CRP levels, statin medication usage, erythrocyte sedimentation rate, body mass index, and disease-modifying antirheumatic drug treatment. The researchers created two cohorts: patients on statin therapy (n=54) and patients not on statin therapy (n=152).

Results indicated that statin therapy significantly benefited patients with PsA by lowering CRP to a median level of 0.2 (interquartile range [IQR], 0.4) when compared with a median level of 0.4 (IQR, 0.6) in the cohort not using a statin medication (P =.003).

The statin cohort also showed a significant correlation between CRP levels and body mass index (rs=0.35, P <.001). While the level of erythrocyte sedimentation rate was not significantly different between the 2 cohorts, the statin cohort had a lower median level than the cohort not on statin medication (5 vs 7, respectively).

Future studies need to evaluate the clinical implication of statin therapy for patients with PsA and explore the relationship between the pathogenesis and disparities in trained immunity for this disease.

Related Articles

In conclusion, early research indicates a potential advantage to statin therapy for patients with PsA by producing a “significant biochemical improvement based on CRP level.”

For more coverage of ACR/ARHP 2018, click here.

Follow @DermAdvisor


Jackson L, Bieber J, Heidel RE. Effect of statins on CRP elevation in patients with psoriatic arthritis. Presented at: ACR Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 2619.

This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.

This article originally appeared on Rheumatology Advisor